StockData

Omada Health vs Privia Health

OMDA and PRVA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How OMDA and PRVA compare

Privia Health is the larger company, worth 3.3 times as much as Omada Health ($3.1B against $933M).

Omada Health grew revenue faster over the last twelve months (43.3% versus 19.2% for Privia Health).

Omada Health keeps more of each dollar of sales as profit, with a net margin of 4.2% compared with 1.4% at Privia Health.

Privia Health scores higher on the StockData Score (15 against 13 for Omada Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricOMDAPRVA
Size and price
Market cap$933M$3.1B
Share price$15.24$24.04
Change, 1 year−26.2%2.7%
Change, 5 years–−16.7%
Beta (5Y)2.380.65
Employees9161,226
StockData Score
Total score1315 (better)
Valuation score12 (better)
Growth score33
Performance score34 (better)
Health score66
Dividend score00
Valuation
P/E–92.5×
P/S2.8×1.3× (better)
P/B3.4× (better)3.8×
EV/EBITDA52.7×42.0× (better)
P/FCF33.1×–
FCF yield3.0%–
Fair value$9.26$15.41
Margin of safety−64.5%−56.0% (better)
Growth
Revenue growth (TTM)43.3% (better)19.2%
Revenue growth, 5Y average–21.0%
Net income growth (TTM)–91.3%
EPS growth (TTM)–100%
EPS growth, 5Y average–−11.4%
Profitability
Gross margin70.7%–
Operating margin2.1%2.1% (better)
Net margin4.2% (better)1.4%
FCF margin8.5%–
Return on equity5.7% (better)4.6%
Return on invested capital28.2% (better)10.0%
Financial health
Debt / equity0.000.00
Interest coverage22.4×–
Current ratio4.18 (better)1.63
Altman Z-score7.47 (better)4.54
Piotroski F-score7 (better)6
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions85.9%96.7%
Held by insiders5.4%7.1%
Insider net buying, 12 months−$14.6M (better)−$22.2M
Superinvestors holding–1
Short interest, % of float15.8%3.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.